Evaluation of metabolic control using a continuous subcutaneous glucose monitoring system in patients with type 1 diabetes mellitus who achieved insulin independence after islet cell transplantation

Milene C. Geiger, Jacqueline V. Ferreira, Muhammad M. Hafiz, Tatiana Froud, David A. Baidal, Luigi F. Meneghini, Camille Ricordi, Rodolfo Alejandro

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

This study evaluated the Medtronic MiniMed Continuous Glucose Monitoring System (CGMS) in patients with type 1 diabetes mellitus who underwent successful islet cell transplantation (ICT). The results are compared to standardized self-monitoring (SMBG) of hyperglycemia and mean amplitude of glycemic excursions (MAGE). We studied 19 patients (mean age 40.0 ± 6.7 years) in three groups: six patients post-ICT, seven patients awaiting ICT, and six normal volunteers (controls). Continuous glucose monitoring post-ICT showed remarkable glucose stability compared with patients awaiting ICT. The CGMS group showed modestly higher glucoses (mean 111.5 mg/dl) compared with controls (88 mg/dl). Postprandial glucoses in ICT recipients rarely exceeded 180 mg/dl and were similar to controls. There was no difference in asymptomatic hypoglycemia between control and post-ICT groups. However, a higher incidence of hypoglycemia was observed in patients awaiting ICT. HbA1c and MAGE pre-and post-ICT were 8.3 ± 0.9% and 6 ± 0.3% (p < 0.001) and 109 ± 34 and 41 ± 11 (p < 0.001), respectively. No complications were associated with CGMS. This study suggests ICT significantly improves metabolic control and rate of hypoglycemia when compared with controls and patients awaiting ICT. Similar improvement in metabolic control was observed with SMBG, HbA1c, and MAGE. Although CGMS was not demonstrated to be a superior tool for routine assessment in ICT, it is very helpful in special clinical situations.

Original languageEnglish (US)
Pages (from-to)77-84
Number of pages8
JournalCell Transplantation
Volume14
Issue number2-3
StatePublished - 2005

Fingerprint

Islets of Langerhans Transplantation
Insulin
Cell Transplantation
Medical problems
Type 1 Diabetes Mellitus
Islets of Langerhans
Glucose
Monitoring
Hypoglycemia
Hyperglycemia
Healthy Volunteers

Keywords

  • Continuous glucose monitoring
  • Diabetes
  • Islet

ASJC Scopus subject areas

  • Cell Biology
  • Transplantation

Cite this

Evaluation of metabolic control using a continuous subcutaneous glucose monitoring system in patients with type 1 diabetes mellitus who achieved insulin independence after islet cell transplantation. / Geiger, Milene C.; Ferreira, Jacqueline V.; Hafiz, Muhammad M.; Froud, Tatiana; Baidal, David A.; Meneghini, Luigi F.; Ricordi, Camille; Alejandro, Rodolfo.

In: Cell Transplantation, Vol. 14, No. 2-3, 2005, p. 77-84.

Research output: Contribution to journalArticle

Geiger, Milene C. ; Ferreira, Jacqueline V. ; Hafiz, Muhammad M. ; Froud, Tatiana ; Baidal, David A. ; Meneghini, Luigi F. ; Ricordi, Camille ; Alejandro, Rodolfo. / Evaluation of metabolic control using a continuous subcutaneous glucose monitoring system in patients with type 1 diabetes mellitus who achieved insulin independence after islet cell transplantation. In: Cell Transplantation. 2005 ; Vol. 14, No. 2-3. pp. 77-84.
@article{7f43cc1668e84a4387c3c004916a006f,
title = "Evaluation of metabolic control using a continuous subcutaneous glucose monitoring system in patients with type 1 diabetes mellitus who achieved insulin independence after islet cell transplantation",
abstract = "This study evaluated the Medtronic MiniMed Continuous Glucose Monitoring System (CGMS) in patients with type 1 diabetes mellitus who underwent successful islet cell transplantation (ICT). The results are compared to standardized self-monitoring (SMBG) of hyperglycemia and mean amplitude of glycemic excursions (MAGE). We studied 19 patients (mean age 40.0 ± 6.7 years) in three groups: six patients post-ICT, seven patients awaiting ICT, and six normal volunteers (controls). Continuous glucose monitoring post-ICT showed remarkable glucose stability compared with patients awaiting ICT. The CGMS group showed modestly higher glucoses (mean 111.5 mg/dl) compared with controls (88 mg/dl). Postprandial glucoses in ICT recipients rarely exceeded 180 mg/dl and were similar to controls. There was no difference in asymptomatic hypoglycemia between control and post-ICT groups. However, a higher incidence of hypoglycemia was observed in patients awaiting ICT. HbA1c and MAGE pre-and post-ICT were 8.3 ± 0.9{\%} and 6 ± 0.3{\%} (p < 0.001) and 109 ± 34 and 41 ± 11 (p < 0.001), respectively. No complications were associated with CGMS. This study suggests ICT significantly improves metabolic control and rate of hypoglycemia when compared with controls and patients awaiting ICT. Similar improvement in metabolic control was observed with SMBG, HbA1c, and MAGE. Although CGMS was not demonstrated to be a superior tool for routine assessment in ICT, it is very helpful in special clinical situations.",
keywords = "Continuous glucose monitoring, Diabetes, Islet",
author = "Geiger, {Milene C.} and Ferreira, {Jacqueline V.} and Hafiz, {Muhammad M.} and Tatiana Froud and Baidal, {David A.} and Meneghini, {Luigi F.} and Camille Ricordi and Rodolfo Alejandro",
year = "2005",
language = "English (US)",
volume = "14",
pages = "77--84",
journal = "Cell Transplantation",
issn = "0963-6897",
publisher = "Cognizant Communication Corporation",
number = "2-3",

}

TY - JOUR

T1 - Evaluation of metabolic control using a continuous subcutaneous glucose monitoring system in patients with type 1 diabetes mellitus who achieved insulin independence after islet cell transplantation

AU - Geiger, Milene C.

AU - Ferreira, Jacqueline V.

AU - Hafiz, Muhammad M.

AU - Froud, Tatiana

AU - Baidal, David A.

AU - Meneghini, Luigi F.

AU - Ricordi, Camille

AU - Alejandro, Rodolfo

PY - 2005

Y1 - 2005

N2 - This study evaluated the Medtronic MiniMed Continuous Glucose Monitoring System (CGMS) in patients with type 1 diabetes mellitus who underwent successful islet cell transplantation (ICT). The results are compared to standardized self-monitoring (SMBG) of hyperglycemia and mean amplitude of glycemic excursions (MAGE). We studied 19 patients (mean age 40.0 ± 6.7 years) in three groups: six patients post-ICT, seven patients awaiting ICT, and six normal volunteers (controls). Continuous glucose monitoring post-ICT showed remarkable glucose stability compared with patients awaiting ICT. The CGMS group showed modestly higher glucoses (mean 111.5 mg/dl) compared with controls (88 mg/dl). Postprandial glucoses in ICT recipients rarely exceeded 180 mg/dl and were similar to controls. There was no difference in asymptomatic hypoglycemia between control and post-ICT groups. However, a higher incidence of hypoglycemia was observed in patients awaiting ICT. HbA1c and MAGE pre-and post-ICT were 8.3 ± 0.9% and 6 ± 0.3% (p < 0.001) and 109 ± 34 and 41 ± 11 (p < 0.001), respectively. No complications were associated with CGMS. This study suggests ICT significantly improves metabolic control and rate of hypoglycemia when compared with controls and patients awaiting ICT. Similar improvement in metabolic control was observed with SMBG, HbA1c, and MAGE. Although CGMS was not demonstrated to be a superior tool for routine assessment in ICT, it is very helpful in special clinical situations.

AB - This study evaluated the Medtronic MiniMed Continuous Glucose Monitoring System (CGMS) in patients with type 1 diabetes mellitus who underwent successful islet cell transplantation (ICT). The results are compared to standardized self-monitoring (SMBG) of hyperglycemia and mean amplitude of glycemic excursions (MAGE). We studied 19 patients (mean age 40.0 ± 6.7 years) in three groups: six patients post-ICT, seven patients awaiting ICT, and six normal volunteers (controls). Continuous glucose monitoring post-ICT showed remarkable glucose stability compared with patients awaiting ICT. The CGMS group showed modestly higher glucoses (mean 111.5 mg/dl) compared with controls (88 mg/dl). Postprandial glucoses in ICT recipients rarely exceeded 180 mg/dl and were similar to controls. There was no difference in asymptomatic hypoglycemia between control and post-ICT groups. However, a higher incidence of hypoglycemia was observed in patients awaiting ICT. HbA1c and MAGE pre-and post-ICT were 8.3 ± 0.9% and 6 ± 0.3% (p < 0.001) and 109 ± 34 and 41 ± 11 (p < 0.001), respectively. No complications were associated with CGMS. This study suggests ICT significantly improves metabolic control and rate of hypoglycemia when compared with controls and patients awaiting ICT. Similar improvement in metabolic control was observed with SMBG, HbA1c, and MAGE. Although CGMS was not demonstrated to be a superior tool for routine assessment in ICT, it is very helpful in special clinical situations.

KW - Continuous glucose monitoring

KW - Diabetes

KW - Islet

UR - http://www.scopus.com/inward/record.url?scp=18044388913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18044388913&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 77

EP - 84

JO - Cell Transplantation

JF - Cell Transplantation

SN - 0963-6897

IS - 2-3

ER -